United States Pharmaceuticals and Healthcare Industry Update Quarter 1 2012
$ 1 088
- January 2013
- by Business Monitor International
- 107
Includes 3 FREE quarterly updates
BMI View: Despite assertions from some stakeholders, the re-election of Barack Obama as President of
the United States is not bad news for pharmaceutical companies and medical device manufacturers,
primarily because we expect continuation of existing policies that have generally been favourable.
However, we caution that further reforms to the healthcare sector are inevitable, due to unsustainable
spending on medical services, by both the public and private sectors.
Headline Expenditure Projections
• Pharmaceuticals: US$337.1bn in 2011 to US$343.1bn in 2012; +1.3% growth in local currency
terms. Forecast slightly down from Q412.
• Healthcare: US$2,708bn in 2011 to US$2,844bn in 2012; +5.0% growth in local currency
terms. Forecast slightly down from Q412.
• Medical devices: US$133bn in 2011 to US$138bn in 2012; +4.6% growth in local currency
terms. Forecast slightly down from Q412.
Executive Summary 7
SWOT Analysis . 9
US Pharmaceuticals And Healthcare Industry SWOT . 9
United States Political SWOT . 10
United States Economic SWOT 10
United States Business Environment SWOT . 11
Pharmaceutical Risk/Reward Ratings . 12
Table: Americas Pharmaceutical Risk/Reward Ratings, Q113 12
Rewards 13
Risks 14
US - Market Summary 15
Regulatory Regime 17
Innovative Drug Regulations 18
Prescription Drug User Fee Act (PDUFA) 20
Generic Drug Regulations . 21
Biosimilar Regulations 24
OTC Medicine Regulations 26
Medical Device Regulations . 26
Promotion Regulations 27
Intellectual Property Regulations . 30
Pricing And Reimbursement Environment 31
Part D 33
Industry Developments . 34
Epidemiology 34
Healthcare Sector 35
Research & Development Sector 37
Clinical Trials 38
Contract/Clinical Research Organisations 39
Medical Device Industry . 40
Hospital Sector 40
Industry Forecast Scenario . 42
Pharmaceutical Market Forecast . 42
Table: Pharmaceutical Sales Indicators 2008-2016 44
Key Growth Factors - Industry 45
Table: Healthcare Expenditure Indicators 2008-2016 . 47
Table: Healthcare Governmental Indicators 2008-2016 48
Table: Healthcare Private Indicators 2008-2016 48
Macro Chart Pack - Nominal Growth Picking Up Pace 49
Table: Macro Indicators 56
Prescription Drug Market Forecast . 57
Table: Prescription Drug Sales Indicators 2008-2016 . 58
Table: Top 10 Therapeutic Classes By Sales (US$bn) 59
Table: Top 10 Therapeutic Classes By Dispensed Prescriptions (mn) 59
Patented Drug Market Forecast 60
Table: Patented Drug Market Indicators 2008-2016 . 61
Generic Drug Market Forecast 62
Table: Generic Drug Sales Indicators 2008-2016 63
OTC Medicine Market Forecast 64
Table: OTC Medicine Sales Indicators 2008-2016 . 65
Medical Device Market Forecast 66
Table: Medical Devices Sales Indicators 2008-2016 . 67
Pharmaceutical Trade Forecast 68
Table: Exports and Imports Indicators 2008-2016 . 69
Key Risks To BMI's Forecast Scenario 70
Competitive Landscape 71
Research-Based Industry 71
Table: Top 10 Companies By US Prescription Sales (US$bn) 72
Table: Top 10 Drugs By US Sales (US$bn) . 72
Research-Based Industry - Key Developments 73
Generic Drugmakers . 73
Table: Top 10 Companies By US Dispensed Prescriptions (mn) 74
Drug Distribution Sector 74
Pharmacy Retail Sector 76
Table: US Dispensed Prescription Drug Distribution By Channel Distribution Volume (mn) . 77
Company Profiles . 78
US Companies 78
Pfizer . 78
Merck & Co 82
Eli Lilly . 85
Amgen 88
Watson Pharmaceuticals 91
Foreign Companies 93
GlaxoSmithKline . 93
AstraZeneca 95
Demographic Outlook 97
Table: Population By Age Group, 1990-2020 ('000) . 98
Table: Population By Age Group, 1990-2020 (% of total) 99
Table: Key Population Ratios, 1990-2020 100
Table: Rural And Urban Population, 1990-2020 100
Glossary 101
BMI Methodology 103
How We Generate Our Pharmaceutical Industry Forecasts 103
Pharmaceuticals Business Environment Ratings 104
Risk/Reward Ratings Methodology .104
Ratings Overview 104
Table: Pharmaceutical Business Environment Indicators .105
Weighting 106
Table: Weighting Of Components 106
Sources 106
Prescription Drug in United States
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2021
By Business Monitor International
Source: IMS Health, Pharmaceutical Research and Manufacturers of America (PhRMA), Food and Drug Administrati
- Industries : Prescription Drug
- Countries : United States
- $ 250
- Industry data
- January 2013
Yearly, From 2003 To 2021
By Business Monitor International
Source: IMS Health, Pharmaceutical Research and Manufacturers of America (PhRMA), Food and Drug Administrati
- Industries : Prescription Drug
- Countries : United States
- $ 250
- Industry data
- January 2013
Yearly, From 2003 To 2021
By Business Monitor International
Source: IMS Health, Pharmaceutical Research and Manufacturers of America (PhRMA), Food and Drug Administrati
- Industries : Prescription Drug
- Countries : United States
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2021
By Business Monitor International
Source: IMS Health, Pharmaceutical Research and Manufacturers of America (PhRMA), Food and Drug Administrati
- Industries : Prescription Drug
- Countries : United States
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2021
By Business Monitor International
Source: IMS Health, Pharmaceutical Research and Manufacturers of America (PhRMA), Food and Drug Administrati
- Industries : Prescription Drug
- Countries : United States
